Welcome to our dedicated page for vTv Therapeutics SEC filings (Ticker: VTVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on vTv Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into vTv Therapeutics's regulatory disclosures and financial reporting.
vTv Therapeutics Inc. reported $36.8 million in collaboration and license revenue for the six months ended June 30, 2026, driven by a $20.0 million upfront payment from Newsoara and $16.9 million of license revenue recognized upon lifting IP restrictions for its G42 collaboration. This produced operating income of $9.3 million and net income of $11.1 million, compared with a loss a year earlier, although the company still carries an accumulated deficit of $315.6 million.
Research and development spending rose sharply to $17.7 million in the first half, largely to advance cadisegliatin, its Phase 3 oral adjunctive therapy for type 1 diabetes, and supporting studies. Cash and cash equivalents were $86.6 million at June 30, 2026, with net cash used in operating activities of $2.3 million. Management states it expects continued operating losses tied to ongoing trials and anticipates needing substantial additional capital over time despite the recent non-recurring license inflows.
vTv Therapeutics reported second quarter 2026 results and updates on its type 1 diabetes program. For the three months ended June 30, 2026, the company recorded a net loss attributable to shareholders of $13.1 million, or $(1.05) per basic and diluted share, with R&D expenses of $8.8 million and G&A expenses of $5.2 million. No revenue was recognized in the quarter.
For the six months ended June 30, 2026, vTv reported revenue of $36,839 (in thousands) and net income attributable to vTv of 11,080 (in thousands), compared with no revenue and a net loss in the prior-year period. Cash and cash equivalents were $86,643 (in thousands) as of June 30, 2026, and the company expects its cash to fund operations through the anticipated topline data readout from the Phase 3 CATT1 trial of cadisegliatin. Enrollment in CATT1 is expected to complete in the third quarter of 2026, a Phase 2a Hybrid CATT1 trial is planned to start before year end 2026, and a Key Opinion Leader event on cadisegliatin and type 1 diabetes is planned for the fourth quarter of 2026.
vTv Therapeutics Inc. is the subject of an amended Schedule 13G filing reporting beneficial ownership of its Class A common stock by several Millennium-affiliated entities and Israel A. Englander. Integrated Core Strategies (US) LLC reports beneficial ownership of 249,027 shares of Class A common stock, representing 6.3% of the class, all with shared voting and dispositive power.
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each report beneficial ownership of 269,874 shares, representing 6.9% of the Class A common stock, with shared voting and dispositive power and no sole voting or dispositive power. The filing explains that securities are held by entities subject to voting control and investment discretion by Millennium Management LLC and related managers, and it states that this structure is not, by itself, an admission of beneficial ownership. A joint filing agreement among the reporting persons is included as an exhibit.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
vTv Therapeutics Inc. reported that director Dr. Raymond Cheong received a grant of 6,000 non-qualified stock options exercisable into Class A common stock at $35.08 per share. The options vest on the earlier of June 26, 2027 or the 2027 annual shareholder meeting and expire on June 26, 2036.
According to the disclosure, the options were granted to Dr. Cheong in his capacity as a director, but the grant is reported for Baker Bros.–affiliated funds because they hold an indirect proportionate pecuniary interest. The adviser to the funds holds voting and dispositive power over the options and any resulting shares, while Dr. Cheong does not retain compensation rights under adviser policies.
vTv Therapeutics Inc. held its 2026 Annual Meeting of Stockholders on June 26, 2026. Stockholders elected seven directors, including Srinivas Akkaraju, Raymond Cheong, Fahed Al Marzooqi, Richard S. Nelson, Anne Phillips, Paul Sekhri, and Daniel K. Spiegelman, each to serve until the 2027 annual meeting or until a successor is elected and qualified.
Stockholders also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, with 2,964,869 votes for, 1,952 against, and 2,869 abstentions. In addition, they cast a nonbinding advisory vote on executive compensation, with 686,535 votes for, 5,291 against, 1,967,329 abstentions, and 310,535 broker non-votes.
SPIEGELMAN DANIEL K reported acquisition or exercise transactions in this Form 4 filing.
vTv Therapeutics Inc. director Daniel K. Spiegelman received a grant of stock options, giving him the right to buy 6,000 shares of Class A Common Stock at $35.08 per share. These options expire on June 26, 2036 and are part of his director compensation.
The options vest on the earlier of June 26, 2027 or the date of the 2027 annual general meeting of shareholders, conditioned on his continued board service through vesting. Following this grant, Spiegelman holds options on a total of 16,000 shares.
vTv Therapeutics Inc. director Srinivas Akkaraju received a grant of stock options covering 6,000 shares of Class A common stock. The options have an exercise price of $35.08 per share and expire on June 26, 2036. According to the terms, the award vests on the earlier of June 26, 2027 and the date of the 2027 annual general meeting of shareholders, provided he continues serving on the board. Following this grant, his total directly held option awards reported in this filing increased to 16,983 derivative securities.
vTv Therapeutics Inc. director Fahed Al-Marzooqi received a grant of stock options covering 6,000 shares of Class A common stock at an exercise price of $35.08 per share. These options vest on the earlier of June 26, 2027 and the 2027 annual general meeting of shareholders, conditioned on continued board service, and expire on June 26, 2036. Following this grant, his reported derivative holdings tied to this award total 19,555 options.
vTv Therapeutics Inc. director Anne M. Phillips received a grant of options to buy 6,000 shares of Class A common stock at an exercise price of $35.08 per share. These director stock options expire on June 26, 2036 and are part of her board compensation.
The option vests on the earlier of June 26, 2027 or the date of the 2027 annual general meeting of shareholders, provided she continues serving on the board through that date. Following this grant, she holds options covering 16,860 shares directly.
vTv Therapeutics Inc. is offering up to $47,500,000 of Class A common stock in an at-the-market offering through TD Cowen pursuant to a sales agreement dated previously. Sales may occur from time to time, with TD Cowen acting as agent or principal and receiving a 3.0% commission.
The prospectus supplement assumes for illustration the sale of 1,559,422 shares at the last reported sale price of $30.46 per share and states there were 3,938,654 shares outstanding as of March 31, 2026. Net proceeds are intended for general corporate purposes, including funding development and trials for cadisegliatin.